Compare SHMD & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | IVVD |
|---|---|---|
| Founded | 1864 | 2020 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 212.6M |
| IPO Year | 2023 | 2021 |
| Metric | SHMD | IVVD |
|---|---|---|
| Price | $2.98 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 1.3M | ★ 5.6M |
| Earning Date | 11-25-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $49.82 | $12.40 |
| Revenue Next Year | $36.39 | $44.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $2.93 | $0.53 |
| 52 Week High | $10.65 | $3.07 |
| Indicator | SHMD | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 40.08 |
| Support Level | N/A | $0.53 |
| Resistance Level | $3.65 | $1.02 |
| Average True Range (ATR) | 0.38 | 0.06 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 3.23 | 16.35 |
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.